SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Course Reviewer
Robert S. Busch, MD, FACE
Director of Clinical Research
Albany Medical Faculty: Community Endocrine Group
Albany, NY


Medical Writer
Cedric Nazareth, MBBS

Title
: Advances in Insulin Therapy: Another Step Closer to a More Physiological Strategy
Activity/Course #:
: NCME366
Cost:
: Free
Release/Start Date:
: Oct 31 2018
Expiration Date:
: Oct 30 2019
Topics:
: Diabetes
Target Audience:
: Primary Care Physicians, Nurse Practitioners, Physician Assistants
Format:
: Monograph
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Summary
Diabetes affects 30.3 million people, approximately 9.4% of the U.S population, with type 2 diabetes (T2DM) accounting for about 90-95% of diagnosed cases in adults. Diabetes is associated with an increased risk for microvascular and macrovascular complications and is the seventh leading cause of death in the United States.

The primary focus of T2DM management is glycemic control; simultaneous management of cardiometabolic risk factors, including blood pressure, lipid profile and overweight/obesity, is associated with improved outcomes. Obesity is associated with increasing insulin resistance, necessitating the use of higher insulin doses for achieving/maintaining glycemic control. Several treatment options including various insulin preparations are available, but glycemic control remains suboptimal.

This activity will examine clinician and patient barriers to initiation and intensification of insulin therapy, the clinical impact of hypoglycemia, the differences and impact of current and long-acting concentrated insulins and provide strategies for incorporating new basal and concentrated insulins into clinical practice.

Learning Objective(s):

After completing this program participants should be able to:

  1. Discuss clinician and patient barriers to initiation and intensification of insulin therapy
  2. Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk
  3. Discuss the pharmacology and clinical differences between existing and new long-acting and concentrated insulins
  4. Discuss how to incorporate new basal and concentrated insulins into clinical practice while minimizing the risk of adverse events

How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hours of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Activity Planning Committee,
Dr. Busch serves as a speaker for Novo Nordisk, Sanofi, AstraZeneca and Lilly. He also serves as a researcher for Novo Nordisk, Sanofi and AstraZeneca.

Gregg Sherman, MD, has no relationships to disclose.

Cedrick Nazareth, Medical Writer, has no relationships to disclose.

Deborah Paschal, CRNP, has no relationships to disclose.

Harvey C. Parker, Ph.D., has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Sanofi US.